Restoring function of the central nervous system is a challenging task. The large cell replacement experience has offered promising results with different types of cells. Here we propose the adult brain cell auto transplantation as an attractive restoration alternative.
The strategy of autologous reimplantation was investigated in two monkey models:motor cortex lesion as a model of stroke and MPTP-treated monkeys as a parkinsonian model. Primocultures were obtained from cortical biopsy. Cells were grown in vitro as neuralcell ecosystem that consist in astrocytes and neural progenitors. In both models the cells survived and were migrated to the affected structures, respectively to the lesion area and the striatal structures. Significant functional recoveries were thus observed in both models.
Based on such preclinical result, a phase I-II clinical trial is planned for application inpatients affected by stroke.
Prior to that clinical trial, the cell production has to be performed in GMP conditions.For that purpose, and other applications in cell therapy, our public institution, the Lausanne University hospital, implemented a Cell Production Center (CPC) that is now accredited by Swissmedic (authorization n°507482). At the CPC an original concept with a module for production, Isocell Pro 1.8, was developed and qualified. This equipment concept allows to maintain a hermetically culture production in a class A environment by working in class D for operators.
As we all know, the way is long and costing from research to clinical applications. The Lausanne University hospital (CHUV) found a way to help teams of clinicians and researchers to approach that challenge in regenerative medicine